# US 2024/0398956 A1 · Biodegradable lipids for the delivery of active agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0398956 A1
- Document ID: US20240398956A1
- Status: Published application
- Kind: A1
- Application number: 18/541,755
- Filed: 2023-12-15
- Published: 2024-12-05
- Earliest claimed: 2011-12-07
- Assignees: Alnylam Pharmaceuticals, Inc.
- Applicants: Alnylam Pharmaceuticals, Inc.
- Inventors: Martin MAIER; Muthusamy JAYARAMAN; Akin AKINC; Shigeo MATSUDA; Pachamuthu KANDASAMY; Kallanthottathil G. RAJEEV; Muthiah MANOHARAN
- Web page: https://patentgrep.com/patent/US20240398956A1

## CPC

- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- C07C 31/125: containing five to twenty-two carbon atoms
- C07C 211/09: Diamines
- C07C 211/10: Diaminoethanes
- C07C 211/11: Diaminopropanes
- C07C 217/08: the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
- C07C 229/12: to carbon atoms of acyclic carbon skeletons
- C07C 235/06: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C 251/38: to carbon atoms of a saturated carbon skeleton
- C07C 323/12: the carbon skeleton being acyclic and saturated
- C07C 323/58: with amino groups bound to the carbon skeleton
- C07C 327/22: having carbon atoms of esterified thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C 327/28: having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
- C07C 327/32: having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
- C07D 207/32: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 233/54: having two double bonds between ring members or between ring members and non-ring members
- C07D 295/08: substituted by singly bound oxygen or sulfur atoms
- C07D 295/12: substituted by singly or doubly bound nitrogen atoms (nitro radicals C07D295/06)
- C07D 295/14: substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 317/30: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07F 5/022: {without C-boron linkages}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A lipid nanoparticle comprising
(a) a nucleic acid;
(b) a cationic lipid, and
(c) a neutral lipid,
wherein the cationic lipid is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 21 (depends on 20)

The lipid nanoparticle of claim 20, further comprising a PEG-modified lipid.

### Claim 22 (depends on 20)

The lipid nanoparticle of claim 20, further comprising a sterol.

### Claim 23 (depends on 20)

The lipid nanoparticle of claim 20, comprising the cationic lipid, the neutral lipid, a PEG-modified lipid, and a sterol.

### Claim 24 (depends on 23)

The lipid nanoparticle of claim 23, comprising about 25 mol % to about 75 mol % of the cationic lipid, wherein the mol % is based on 100% total moles of lipids in the lipid nanoparticle.

### Claim 25 (depends on 24)

The lipid nanoparticle of claim 24, comprising about 35 mol % to about 65 mol % of the cationic lipid.

### Claim 26 (depends on 24)

The lipid nanoparticle of claim 24, comprising about 45 mol % to about 65 mol % of the cationic lipid.

### Claim 27 (depends on 23)

The lipid nanoparticle of claim 23, comprising no more than about 15 mol % of the neutral lipid, wherein the mol % is based on 100% total moles of lipids in the lipid nanoparticle.

### Claim 28 (depends on 27)

The lipid nanoparticle of claim 27, comprising about 3 mol % to about 12 mol % of the neutral lipid.

### Claim 29 (depends on 23)

The lipid nanoparticle of claim 23, wherein the neutral lipid is dipalmitoylphosphatidylcholine (DPPC) or distearylphosphatidylcholine (DSPC).

### Claim 30 (depends on 23)

The lipid nanoparticle of claim 23, comprising about 5 mol % to about 50 mol % of the sterol, wherein the mol % is based on 100% total moles of lipids in the lipid nanoparticle.

### Claim 31 (depends on 30)

The lipid nanoparticle of claim 30, comprising about 15 mol % to about 45 mol % of the sterol.

### Claim 32 (depends on 23)

The lipid nanoparticle of claim 23, wherein the sterol is cholesterol.

### Claim 33 (depends on 23)

The lipid nanoparticle of claim 23, comprising about 0.1 mol % to about 20 mol % of the PEG-modified lipid, wherein the mol % is based on 100% total moles of lipids in the lipid nanoparticle.

### Claim 34 (depends on 33)

The lipid nanoparticle of claim 33, comprising about 0.5 mol % to about 10 mol % of the PEG-modified lipid.

### Claim 35 (depends on 23)

The lipid nanoparticle of claim 23, wherein the PEG-modified lipid is PEG-DMG or PEG-c-DMA.

### Claim 36 (depends on 23)

The lipid nanoparticle of claim 23, wherein the PEG-modified lipid comprises a PEG molecule having an average PEG molecular weight of 2000 Da.

### Claim 37 (depends on 23)

The lipid nanoparticle of claim 23, wherein the PEG-modified lipid is 1-(monomethoxy-polyethyleneglycol)-2,3-dimyristoylglycerol (PEG-DMG) comprising a PEG molecule having an average molecular weight of 2,000 Da.

### Claim 38 (depends on 23)

The lipid nanoparticle of claim 23, comprising
about 25 mol % to about 75 mol % of the cationic lipid,
about 0.5 mol % to about 15 mol % of the neutral lipid,
about 5 mol % to about 50 mol % of the sterol, and
about 0.5 mol % to about 20 mol % of the PEG-modified lipid;
wherein the mol % is based on 100% total moles of lipids in the lipid nanoparticle.

### Claim 39 (depends on 23)

The lipid nanoparticle of claim 23, comprising
about 35 mol % to about 65 mol % of the cationic lipid,
about 3 mol % to about 12 mol % of the neutral lipid,
about 15 mol % to about 45 mol % of the sterol, and
about 0.5 mol % to about 10 mol % of the PEG-modified lipid;
wherein the mol % is based on 100% total moles of lipids in the lipid nanoparticle.

### Claim 40 (depends on 23)

The lipid nanoparticle of claim 23, comprising
about 45 mol % to about 65 mol % of the cationic lipid,
about 5 mol % to about 10 mol % of the neutral lipid,
about 25 mol % to about 40 mol % of the sterol, and
about 0.5 mol % to about 5 mol % of the PEG-modified lipid;
wherein the mol % is based on 100% total moles of lipids in the lipid nanoparticle.

### Claim 41 (depends on 23)

The lipid nanoparticle of claim 23, comprising
about 50 mol % of the cationic lipid,
about 10 mol % distearoylphosphatidylcholine (DSPC),
about 38.5 mol % cholesterol, and
about 1.5 mol % of the PEG-modified lipid,
wherein the mol % is based on 100% total moles of lipids in the lipid nanoparticle.

### Claim 42 (depends on 23)

The lipid nanoparticle of claim 23, wherein the nucleic acid is an RNA.

### Claim 43 (depends on 42)

The lipid nanoparticle of claim 42, wherein the nucleic acid is a single stranded RNA.

### Claim 44 (depends on 42)

The lipid nanoparticle of claim 42, wherein the nucleic acid is a double stranded RNA.

### Claim 45 (depends on 23)

The lipid nanoparticle of claim 23, wherein the nucleic acid is a single stranded DNA.

### Claim 46 (depends on 23)

The lipid nanoparticle of claim 23, wherein the nucleic acid is a double stranded DNA.

### Claim 47 (depends on 23)

The lipid nanoparticle of claim 23, wherein the nucleic acid is a DNA-RNA hybrid.

### Claim 48 (depends on 23)

A pharmaceutical composition comprising a lipid nanoparticle according to claim 23 and a pharmaceutically acceptable diluent.

### Claim 49 (depends on 48)

The pharmaceutical composition of claim 48, wherein the pharmaceutically acceptable diluent comprises phosphate buffered saline or physiological saline.

### Claim 50 (depends on 23)

A method of modulating the expression of a target gene in a cell, comprising providing to the cell a lipid nanoparticle of claim 23.

### Claim 51 (depends on 50)

The method of claim 50, wherein the cell is in a human.

### Claim 52 (depends on 50)

The method of claim 50, wherein the nucleic acid is an RNA.

### Claim 53 (depends on 52)

The method of claim 52, wherein the nucleic acid is a single stranded RNA.

### Claim 54 (depends on 52)

The method of claim 52, wherein the nucleic acid is a double stranded RNA.

### Claim 55 (depends on 50)

The method of claim 50, wherein the nucleic acid is a single stranded DNA.

### Claim 56 (depends on 50)

The method of claim 50, wherein the nucleic acid is a double stranded DNA.

### Claim 57 (depends on 50)

The method of claim 50, wherein the nucleic acid is a DNA-RNA hybrid.

### Claim 58

A lipid nanoparticle comprising
(a) a nucleic acid,
(b) about 35 mol % to about 65 mol % of a cationic lipid,
(c) about 3 mol % to about 12 mol % distearoylphosphatidylcholine (DSPC),
(d) about 0.5 mol % to about 10 mol % 1-(monomethoxy-polyethyleneglycol)-2,3-dimyristoylglycerol (PEG-DMG), and
(e) about 15 mol % to about 45 mol % cholesterol;
wherein
the mol % is based on 100% total moles of lipids in the lipid nanoparticle; and
the cationic lipid is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 59 (depends on 58)

The lipid nanoparticle of claim 58, wherein the nucleic acid is an RNA.

### Claim 60 (depends on 59)

The lipid nanoparticle of claim 59, wherein the nucleic acid is a single stranded RNA.

### Claim 61 (depends on 59)

The lipid nanoparticle of claim 59, wherein the nucleic acid is a double stranded RNA.

### Claim 62 (depends on 58)

The lipid nanoparticle of claim 58, wherein the nucleic acid is a single stranded DNA.

### Claim 63 (depends on 58)

The lipid nanoparticle of claim 58, wherein the nucleic acid is a double stranded DNA.

### Claim 64 (depends on 58)

The lipid nanoparticle of claim 58, wherein the nucleic acid is a DNA-RNA hybrid.

### Claim 65 (depends on 58)

A pharmaceutical composition comprising a lipid nanoparticle according to claim 58 and a pharmaceutically acceptable diluent.

### Claim 66 (depends on 58)

A method of delivering an active agent to a cell, comprising providing to the cell a lipid nanoparticle of claim 58.

### Claim 67 (depends on 66)

The method of claim 66, wherein the nucleic acid is an RNA.

### Claim 68 (depends on 67)

The method of claim 67, wherein the nucleic acid is a single stranded RNA.

### Claim 69 (depends on 67)

The method of claim 67, wherein the nucleic acid is a double stranded RNA.

### Claim 70 (depends on 66)

The method of claim 66, wherein the nucleic acid is a single stranded DNA.

### Claim 71 (depends on 66)

The method of claim 66, wherein the nucleic acid is a double stranded DNA.

### Claim 72 (depends on 66)

The method of claim 66, wherein the nucleic acid is a DNA-RNA hybrid.
